Boehringer Ingelheim and AbGenomics Corporation sign worldwide exclusive collaboration and license agreement
"Monoclonal antibodies are an increasingly important component of medical treatments. AbGenomics Corporation's antibody 168, with its novel mechanism of action, has the potential of introducing a new therapeutic paradigm for the treatment of autoimmune diseases. Our agreement with AbGenomics Corporation is the latest example of our corporate strategy to build long-term growth by focusing on biopharmaceuticals and on potential disease areas with unmet medical needs." said Dr Andreas Barner Vice Chairman of the Board Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim.
"This licensing deal underlines our strategy of collaborating with international pharma partners who bring specialized skills and know-how to accelerate the development and marketing of our compounds. Boehringer Ingelheim, an outstanding company with world-class pharmaceutical business and a world leader in the manufacturing of biopharmaceuticals, is an ideal partner. We are enthusiastic about working with Boehringer Ingelheim and are also very optimistic that this agreement will bring our proprietary monoclonal antibody to patients around the world" commented Dr Rong-Hwa Lin, Chairman of the Board and Chief Executive Officer of AbGenomics Corporation.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.